Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C N Robertson

Showing results (51-60 of 60) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 60 results.
Urology|July 11, 2001
Pilot study of dietary fat restriction and flaxseed supplementation in men with prostate cancer before surgery: exploring the effects on hormonal levels, prostate-specific antigen, and histopathologic featuresW Demark-Wahnefried, D T Price, T J Polascik, et al.
Prostate Cancer and Prostatic Diseases|October 17, 2012
Race is associated with discontinuation of active surveillance of low-risk prostate cancer: results from the Duke Prostate CenterM R Abern, M R Bassett, M Tsivian, et al.
Prostate Cancer and Prostatic Diseases|April 11, 2012
Complete high-intensity focused ultrasound in prostate cancer: outcome from the @-RegistryA Blana, C N Robertson, S C W Brown, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 6, 2000
Early onset baldness and prostate cancer riskW Denmark-Wahnefried, J M Schildkraut, D Thompson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1988
Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot studyS L Topalian, D Solomon, F P Avis, et al.
Prostate Cancer and Prostatic Diseases|June 2, 2010
Predicting non-organ-confined prostate cancer in men diagnosed after 2000A A Caire, L Sun, B D Lack, et al.
The New England Journal of Medicine|April 9, 1987
A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 aloneS A Rosenberg, M T Lotze, L M Muul, et al.
Oncology (Williston Park, N.Y.)|June 23, 1999
QOL and outcomes research in prostate cancer patients with low socioeconomic statusS P Kim, C L Bennett, C Chan, et al.
Prostate Cancer and Prostatic Diseases|August 2, 2006
Timing and patterns of recurrences and deaths from prostate cancer following adjuvant pelvic radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostateM S Anscher, R Clough, C N Robertson, et al.
Prostate Cancer and Prostatic Diseases|March 29, 2017
Patient selection for prostate focal therapy in the era of active surveillance: an International Delphi Consensus ProjectK J Tay, M J Scheltema, H U Ahmed, et al.
Pageof 6

Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
Urology|July 11, 2001
Pilot study of dietary fat restriction and flaxseed supplementation in men with prostate cancer before surgery: exploring the effects on hormonal levels, prostate-specific antigen, and histopathologic featuresW Demark-Wahnefried, D T Price, T J Polascik, et al.
Prostate Cancer and Prostatic Diseases|October 17, 2012
Race is associated with discontinuation of active surveillance of low-risk prostate cancer: results from the Duke Prostate CenterM R Abern, M R Bassett, M Tsivian, et al.
Prostate Cancer and Prostatic Diseases|April 11, 2012
Complete high-intensity focused ultrasound in prostate cancer: outcome from the @-RegistryA Blana, C N Robertson, S C W Brown, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 6, 2000
Early onset baldness and prostate cancer riskW Denmark-Wahnefried, J M Schildkraut, D Thompson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1988
Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot studyS L Topalian, D Solomon, F P Avis, et al.
Prostate Cancer and Prostatic Diseases|June 2, 2010
Predicting non-organ-confined prostate cancer in men diagnosed after 2000A A Caire, L Sun, B D Lack, et al.
The New England Journal of Medicine|April 9, 1987
A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 aloneS A Rosenberg, M T Lotze, L M Muul, et al.
Oncology (Williston Park, N.Y.)|June 23, 1999
QOL and outcomes research in prostate cancer patients with low socioeconomic statusS P Kim, C L Bennett, C Chan, et al.
Prostate Cancer and Prostatic Diseases|August 2, 2006
Timing and patterns of recurrences and deaths from prostate cancer following adjuvant pelvic radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostateM S Anscher, R Clough, C N Robertson, et al.
Prostate Cancer and Prostatic Diseases|March 29, 2017
Patient selection for prostate focal therapy in the era of active surveillance: an International Delphi Consensus ProjectK J Tay, M J Scheltema, H U Ahmed, et al.
Pageof 6